Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immunotherapy Targeting of Cytomegalovirus Antigens in Glioblastoma (INTERROGATE-GBM)

NCT06132438 is registered in ClinicalTrials.gov with Charlotte Lemech as lead sponsor.

NCT NCT06132438
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06132438 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immunotherapy Targeting of Cytomegalovirus Antigens in Glioblastoma (INTERROGATE-GBM)
Lead sponsor
Charlotte Lemech
Phase
Phase 1
Overall status
Recruiting
Start date
July 22, 2024
Completion date
September 30, 2027
Enrollment
26 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma